<SEC-DOCUMENT>0001640334-23-002286.txt : 20231208
<SEC-HEADER>0001640334-23-002286.hdr.sgml : 20231208
<ACCEPTANCE-DATETIME>20231208163106
ACCESSION NUMBER:		0001640334-23-002286
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20231208
DATE AS OF CHANGE:		20231208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275810
		FILM NUMBER:		231475845

	BUSINESS ADDRESS:	
		STREET 1:		100 - 740 MCCURDY ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 2P7
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		100 - 740 MCCURDY ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 2P7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>lxrp_424b3.htm
<DESCRIPTION>FORM 424B3
<TEXT>
<html><head><title>lxrp_424b3.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Filed Pursuant to Rule 424(b)(3)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>Registration No. 333-275810</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>PROSPECTUS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="lxrp_s1img1.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Lexaria Bioscience Corp.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>1,618,330 Shares of Common Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This prospectus relates to the resale by the selling stockholder named in this prospectus from time to time of up to 1,618,330 shares of our common stock, par value $0.001 per share, issuable upon the exercise of outstanding warrants issued in October 2023 (the &#8220;Warrants&#8221;). &nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will not receive any proceeds from the sale of shares of common stock by the selling stockholder. Upon the cash exercise of the Warrants however, we will receive the exercise price of such Warrants, for an aggregate of approximately $1,569,780.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our registration of the shares of common stock covered by this prospectus does not mean that the selling stockholder will offer or sell any of such shares of common stock. The selling stockholder named in this prospectus, or its donees, pledgees, transferees or other successors-in-interest, may resell the shares of common stock covered by this prospectus through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. For additional information on the possible methods of sale that may be used by the selling stockholder, you should refer to the section of this prospectus entitled &#8220;Plan of Distribution&#8221;.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">No </p> <p style="MARGIN: 0px; text-align:justify;">underwriter or other person has been engaged to facilitate the sale of the common stock in this offering. We will bear all costs, expenses and fees in connection with the registration of the common stock. The selling stockholder will bear all commissions and discounts, if any, attributable to its sales of our common stock. </p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;">Our common stock and public warrants are listed respectively on The Nasdaq Capital Market, or Nasdaq, under the symbols &#8220;LEXX&#8221; and &#8220;LEXXW&#8221;. On December 7, 2023, the last reported sales price for our common stock was $1.44 per share and the last reported sales price for our listed warrants was $0.52 per listed warrant.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Investment in our common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; contained in this prospectus on page 4, in our periodic reports filed from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;), which are incorporated by reference in this prospectus, and in any applicable prospectus supplement. You should carefully read this prospectus and the documents we incorporate by reference, before you invest in our common stock.</strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:justify;"><strong>Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or the accuracy of this prospectus. Any representation to the contrary is a criminal offense.</strong></p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px; text-align:center;">The date of this prospectus is December 8, 2023.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="TOC">TABLE OF CONTENTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="#ATP">ABOUT THIS PROSPECTUS</a></p></td> <td style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">1</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="#PS">PROSPECTUS SUMMARY</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">2</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="#TO">THE OFFERING</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">3</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="#RF">RISK FACTORS</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">4</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="#SNRFLS">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">4</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="#UOP">USE OF PROCEEDS</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">5</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="#SS">SELLING STOCKHOLDER</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">5</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="#DSBR">DESCRIPTION OF SECURITIES BEING REGISTERED</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">7</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="#POD">PLAN OF DISTRIBUTION</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">8</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="#LM">LEGAL MATTERS</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">10</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="#EPERT">EXPERTS</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">10</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="#WYCMI">WHERE YOU CAN FIND MORE INFORMATION</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">10</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><a href="#ICIBR">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</a></p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:right;margin:0px">11</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="ATP">ABOUT THIS PROSPECTUS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This prospectus is part of the registration statement that we filed with the SEC pursuant to which the selling stockholder named herein may, from time to time, offer and sell or otherwise dispose of the shares of our common stock covered by this prospectus. As permitted by the rules and regulations of the SEC, the registration statement filed by us includes additional information not contained in this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This prospectus and the documents incorporated by reference into this prospectus include important information about us, the securities being offered and other information you should know before investing in our securities. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus is delivered or shares of common stock are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus, including the documents incorporated by reference therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you under &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference&#8221; in this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">You should rely only on this prospectus and the information incorporated or deemed to be incorporated by reference in this prospectus. We have not, and the selling stockholder has not, authorized anyone to give any information or to make any representation to you other than those contained or incorporated by reference in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unless otherwise indicated, information contained or incorporated by reference in this prospectus concerning our industry, including our general expectations and market opportunity, is based on information from our own management estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. Management estimates are derived from publicly available information, our knowledge of our industry and assumptions based on such information and knowledge, which we believe to be reasonable. In addition, assumptions and estimates of our and our industry&#8217;s future performance are necessarily uncertain due to a variety of factors, including those described in &#8220;Risk Factors&#8221; beginning on page 4 of this prospectus. These and other factors could cause our future performance to differ materially from our assumptions and estimates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.75pt; text-align:justify;"><strong>This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. We are not making an offer to sell these securities in any state or jurisdiction where the offer or sale is not permitted.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="PS">PROSPECTUS SUMMARY</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our securities. You should read this entire prospectus carefully, including the &#8220;Risk Factors&#8221; section in this prospectus and under similar captions in the documents incorporated by reference into this prospectus. In this prospectus, unless otherwise stated or the context otherwise requires, references to &#8220;Lexaria,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or similar references mean Lexaria Bioscience Corp. and/or our subsidiaries on a consolidated basis.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Company Overview</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria Bioscience Corp. is a biotechnology company developing the enhancement of the bioavailability of a broad range of fat-soluble active molecules and active pharmaceutical ingredients (&#8220;APIs&#8221;) using our patented DehydraTECH<sup style="vertical-align:super">TM</sup>&nbsp;drug delivery technology. DehydraTECH combines lipophilic molecules or APIs with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">DehydraTECH can be used with a wide range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Our technology can be applied to a variety of therapeutic indications, including hypertension and heart disease, and diabetes. DehydraTECH can be implemented in a multitude of ingestible or topically administered product formats including foods, beverages, oral suspensions, tablets, capsules, creams, lotions, and skin patches. It is suitable for use with a variety of product formats including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">DehydraTECH is a technology incorporated into the formulation and manufacturing process of new or existing orally ingestible and topical products. The procedure involves fusing the active ingredient as a delivery &#8220;payload&#8221; together with certain fatty acids and infusing the mixture into a substrate material. Using controlled dehydration processing, it combines the payload and fatty acids together at a molecular level. The newly combined molecules are then integrated into production of the end-product using any number of dosage formats. From foods and beverages to cosmetics and nutraceuticals, this technology extends across many product categories beyond the primary pharmaceutical focus of the Company. DehydraTECH formulations have been found in some cases to reduce the need for unwanted sweeteners or chemical masking agents used for flavor- and odor-blocking, allowing manufacturers to create low-sugar products with fewer calories and artificial sweeteners.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has developed extensive experience from the formulation and production of its demonstration products, in various formats, that enables us to provide expert advice to our licensees with the integration of DehydraTECH in their products for the purpose of providing a more palatable and efficient delivery of bioactive molecules.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lexaria supports our licensee&#8217;s products with our technology. A part of our business plan is to encourage new and existing participants to license and utilize DehydraTECH to enable enhanced performance of their products. These products cross a wide range of lipophilic bioactive molecules including nicotine and cannabidiol (&#8220;CBD&#8221;) with additional molecules of interest continually being evaluated.&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Corporate Information</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our principal executive offices are located at 100 &#8211; 740 McCurdy Road, Kelowna, British Columbia, Canada, V1X 2P7. Our telephone number is 1-250-765-6424. We maintain a website at <u>www.lexariabioscience.com</u>. The information contained on our website is not, and should not be interpreted to be, a part of this prospectus. Lexaria Bioscience Corp. is a British Columbia based reporting issuer in Canada and as such, we are required to file certain information and documents at <u>www.sedarplus.ca</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="3" style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong><a name="TO">THE OFFERING</a></strong></p></td></tr> <tr style="height:15px"> <td style="width:20%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Common Stock to be Offered</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">by the Selling Stockholder</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Up to 1,618,330 shares of our common stock which are issuable upon the exercise of the Warrants.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Use of Proceeds</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">All shares of our common stock offered by this prospectus are being registered for the account of the selling stockholder and we will not receive any proceeds from the sale of these shares. However, we will receive proceeds from the exercise of the Warrants if the Warrants are exercised for cash. We intend to use those proceeds, if any, for working capital purposes. See &#8220;Use of Proceeds&#8221; beginning on page&nbsp;5 of this prospectus for additional information.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Plan of Distribution</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">The selling stockholder named in this prospectus, or its pledgees, donees, transferees, distributees, beneficiaries or other successors-in-interest, may offer or sell the shares of common stock from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The selling stockholder may also resell the shares of common stock to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions.</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">See &#8220;Plan of Distribution&#8221; beginning on page 8 of this prospectus for additional information on the methods of sale that may be used by the selling stockholder.</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Nasdaq Capital Market Symbol</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">Our common stock and public warrants are listed on Nasdaq under the symbol &#8220;LEXX&#8221; and &#8220;LEXXW&#8221; respectively. </p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Risk Factors</p></td> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Investing in our common stock involves significant risks. See &#8220;Risk Factors&#8221; beginning on page 4 of this prospectus and the documents incorporated by reference in this prospectus.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="RF">RISK FACTORS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">An investment in our common stock involves a high degree of risk. You should carefully consider the risks set forth under the section captioned &#8220;Risk Factors&#8221; contained in our Annual Report on Form 10-K for the year ended August 31, 2023, which is incorporated by reference into this prospectus, and in the other reports that we file with the SEC and incorporate by reference into this prospectus, before deciding to invest in our common stock. The risks and uncertainties we have described are not the only ones we face.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If any of the events described in these risk factors actually occurs, or if additional risks and uncertainties that are not presently known to us or that we currently deem immaterial later materialize, then our business, prospects, results of operations and financial condition could be materially adversely affected. In that event, the trading price of our securities could decline, and you may lose all or part of your investment in our securities. The risks discussed include forward-looking statements, and our actual results may differ substantially from those discussed in these forward-looking statements. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><a name="SNRFLS">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This prospectus, and any documents we incorporate by reference, contain certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this prospectus and any documents we incorporate by reference, other than statements of historical facts, are forward-looking statements including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The words &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;estimate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;may&#8221;, &#8220;plan&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;will&#8221;, &#8220;would&#8221;, &#8220;could&#8221;, &#8220;should&#8221;, &#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about: the status, progress and results of our research programs; our ability to obtain regulatory approvals for, and the level of market opportunity for, our product candidates; our business plans, strategies and objectives, including plans to pursue collaboration, licensing or other similar arrangements or transactions; our expectations regarding our liquidity and performance, including our expense levels, sources of capital and ability to maintain our operations as a going concern; the competitive landscape of our industry; and general market, economic and political conditions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These forward-looking statements are only predictions and we may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, so you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. We have included important factors in the cautionary statements included in this prospectus that could cause actual future results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">You should read this prospectus with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="UOP">USE OF PROCEEDS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All shares of common stock offered by this prospectus are being registered for the account of the selling stockholder and we will not receive any proceeds from the sale of these shares. However, we will receive proceeds from the exercise of the Warrants if the Warrants are exercised for cash. We intend to use those proceeds, if any, for research and development studies and the patent and legal costs associated thereto, and for general working capital purposes.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="SS">SELLING STOCKHOLDER</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Unless the context otherwise requires, as used in this prospectus, &#8220;selling stockholder&#8221; includes the selling stockholder listed below and donees, pledgees, transferees or other successors-in-interest selling shares received after the date of this prospectus from the selling stockholder as a gift, pledge or other non-sale related transfer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have prepared this prospectus to allow the selling stockholder or its successors, assignees or other permitted transferees to sell or otherwise dispose of, from time to time, up to 1,618,330 shares of our common stock which are issuable upon the exercise of the Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>September 2023 Securities Purchase Agreement &nbsp;</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On September 28, 2023, we entered into a securities purchase agreement with the selling stockholder, pursuant to which we agreed to issue and sell (i) in a registered direct offering, 889,272 shares of common stock at a price of $0.97 per share, and a pre-funded warrant at a price of $707,113.35 to purchase up to 729,058 shares of common stock at an exercise price of $0.0001 per share of common stock, and (ii) in a concurrent private placement, the Warrants, at an exercise price of $0.97 per share. The registered direct offering and concurrent private placement closed on October 3, 2023. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the terms of the securities purchase agreement, we are required to file a registration statement on Form S-1 or other appropriate form registering the resale of the shares of common stock issued and issuable upon the exercise of the Warrants. We are required to use commercially reasonable efforts to cause such registration to become effective within 181 days of the closing date of the offering, and to keep the registration statement effective at all times until no investor owns any Warrants or shares issuable upon exercise thereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Relationship with the Selling Stockholder</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Except as described above under &#8220;September 2023 Securities Purchase Agreement&#8221; and with respect to earlier purchases of our securities in arms-length transactions, the selling stockholder does not have, or within the past three years has not had any position, office, or other material relationship with us.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Information About Selling Stockholder Offering</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The shares of common stock being offered by the selling stockholder are the 1,618,330 shares of our common stock issuable upon the exercise of the Warrants. We are registering these shares in order to permit the selling stockholder to offer the shares for resale from time to time.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The table below lists the selling stockholder and other information regarding the ownership of the shares of common stock by the selling stockholder. The second column lists the number of shares of common stock owned by the selling stockholder, based on its ownership of the shares of common stock as of November 30, 2023 and securities convertible or exercisable into shares of common stock within 60 days of November 30, 2023.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The third column lists the shares of common stock being offered pursuant to this prospectus by the selling stockholder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Name of Selling</strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Stockholder</strong></p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Number of </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>shares of </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>common stock owned prior </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>to offering</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Maximum </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>number of </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>shares of </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>common stock </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>to be sold </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>pursuant </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>to this </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Prospectus</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Number of </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>shares of </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>common stock owned after </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>offering</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>Percentage of common stock owned after </strong></p> <p style="font-size:10pt;font-family:times new roman;text-align:center;margin:0px"><strong>offering</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">Armistice Capital Master Fund Ltd. (1)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">2,278,330</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">(2)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,618,330</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">(3)</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">660,000</td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.99</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">(1) The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the &#8220;Master Fund&#8221;), and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC (&#8220;Armistice Capital&#8221;), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital.&nbsp; The warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the Selling Stockholder from exercising that portion of the warrants that would result in the Selling Stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022. &nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">(2) Includes (i) 660,000 shares of common stock and (ii) 1,618,330 shares of common stock issuable upon exercise of the Warrants, assuming exercise of the Warrants, without regard to any limitations on exercises of the Warrants.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">(3) Includes 1,618,330 shares of common stock issuable upon exercise of the Warrants. The Warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the selling stockholder from exercising that portion of the Warrants that would result in the selling stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="DSBR">DESCRIPTION OF SECURITIES TO BE REGISTERED</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>The following summary of the rights of our capital stock is not complete and is subject to and qualified in its entirety by reference to our Articles of Incorporation and Bylaws, copies of which are filed as exhibits to our Annual Report on Form&nbsp;10-K for the year ended August 31, 2023, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November 20, 2023, and the forms of securities, copies of which are filed as exhibits to the registration statement of which this prospectus forms a part, which are incorporated by reference herein.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Authorized Capital Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our authorized capital stock consists of 220,000,000 shares of common stock, par value $0.001 per share.&nbsp; As of November 30, 2023, there were 10,276,641 shares of common stock outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.75pt; text-align:justify;"><strong>Common Stock</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.75pt; text-align:justify;">We are authorized to issue up to a total of 220,000,000 shares of common stock, par value $0.001 per share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of our stockholders. Holders of our common stock have no cumulative voting rights. Further, holders of our common stock have no preemptive or conversion rights or other subscription rights. Upon our liquidation, dissolution or winding-up, holders of our common stock are entitled to share in all assets remaining after payment of all liabilities. Holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our Board out of our assets which are legally available. Such dividends, if any, are payable in cash, in property or in shares of capital stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.75pt; text-align:justify;">The holders of shares of our common stock equal to 33.33% of all of our outstanding capital stock, present in person or by proxy, are necessary to constitute a quorum at any shareholder meeting. If a quorum is present, an action by stockholders entitled to vote on a matter is approved if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to the action. The vote of a majority of our stock held by shareholders present in person or represented by proxy and entitled to vote at the meeting will be sufficient to elect directors or to approve a proposal. The additional shares of our authorized capital stock available for issuance may be issued at times and under circumstances so as to have a dilutive effect on earnings per share and on the equity ownership of the holders of our common stock. The ability of our board of directors to issue additional shares of stock could enhance the board&#8217;s ability to negotiate on behalf of the stockholders in a takeover situation but could also be used by the board to make a change of control more difficult, thereby denying stockholders the potential to sell their shares at a premium and entrenching current management. The following description is a summary of the material provisions of our capital stock. You should refer to our Articles of Incorporation and our Bylaws, each as amended to date, both of which are on file with the SEC as exhibits to previous SEC filings, for additional information. The summary below is qualified by provisions of applicable law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="POD">PLAN OF DISTRIBUTION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The selling stockholder, including its pledgees, donees, transferees, distributees, beneficiaries or other successors in interest may, from time to time, offer some or all of the shares of common stock covered by this prospectus. We will not receive any of the proceeds from the sale of the shares of common stock covered by this prospectus by the selling stockholder. However, we will receive proceeds from the exercise of the Warrants if the Warrants are exercised for cash. We intend to use those proceeds, if any, for working capital purposes. We will bear all fees and expenses incident to our obligation to register the shares of our common stock covered by this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The selling stockholder may sell all or a portion of the shares of common stock beneficially owned by it and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the shares of common stock are sold through underwriters or broker-dealers, the selling stockholder will be responsible for underwriting discounts or commissions or agent&#8217;s commissions. The shares of common stock may be sold on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, in the over-the-counter market or in transactions otherwise than on these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at privately negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The selling stockholder may use any one or more of the following methods when disposing of shares:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</p> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">an over-the-counter distribution;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">an exchange distribution in accordance with the rules of the applicable exchange;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">privately negotiated transactions;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">short sales effected after the effective date of the registration statement of which this prospectus is a part;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">broker-dealers may agree with the selling stockholder to sell a specified number of such shares at a stipulated price per share;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">a combination of any such methods of sale; or</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&#9679;</p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">any other method permitted pursuant to applicable law.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The selling stockholder may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by it and, if it defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending the list of the selling stockholder to include the selling stockholder&#8217;s pledgee, transferee, or other successors in interest as selling stockholder under this prospectus. The selling stockholder also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the sale of shares of our common stock, the selling stockholder may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholder may also sell shares of our common stock short and deliver these shares to close out its short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these shares. The selling stockholder may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Broker-dealers engaged by the selling stockholder may arrange for other broker-dealers to participate in sales. If the selling stockholder effects certain transactions by selling shares of common stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholder or commissions from purchasers of the shares of common stock for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with applicable FINRA rules; and in the case of a principal transaction a markup or markdown in compliance with applicable FINRA rules.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The aggregate proceeds to the selling stockholder from the sale of the common stock offered by it will be the purchase price of the common stock less discounts or commissions, if any. The selling stockholder reserves the right to accept and, together with its agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The selling stockholder also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that it meets the criteria and conforms to the requirements of that rule.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The selling stockholder and any underwriters, broker-dealers or agents that participate in the sale of the common stock may be deemed to be &#8220;underwriters&#8221; within the meaning of Section 2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. The selling stockholder is subject to the prospectus delivery requirements of the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To the extent required pursuant to Rule 424(b) under the Securities Act, the shares of our common stock to be sold, the name of the selling stockholder, the purchase price and public offering price, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states, the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The selling stockholder and any other person participating in a sale of the common stock registered under this prospectus will be subject to applicable provisions of the Exchange Act, and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of common stock by the selling stockholder and any other participating person. All of the foregoing may affect the marketability of the shares of common stock and the ability of any person or entity to engage in market-making activities with respect to the shares of common stock. In addition, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholder for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholder may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="LM">LEGAL MATTERS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The validity of the securities offered by this prospectus will be passed upon by Sichenzia Ross Ference Carmel, LLP, New York, New York.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="EPERT">EXPERTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The consolidated financial statements of the Company as of and for the year ended August 31, 2023, included in our Annual Report on Form 10-K for the year ended August 31, 2023, have been audited by MaloneBailey, LLP, independent registered public accounting firm, as stated in their report, and have been incorporated by reference herein in reliance on the report of such firm given upon their authority as experts in accounting and auditing.&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The consolidated financial statements of the Company for the year ended August 31, 2022, included in the August 31, 2023 Annual Report on Form 10-K the Company have been incorporated by reference herein and in the registration statement in reliance upon the report of Davidson &amp; Company LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="WYCMI">WHERE YOU CAN FIND MORE INFORMATION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are subject to the informational requirements of the Exchange Act and in accordance therewith file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the SEC&#8217;s website is www.sec.gov.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We make available free of charge on or through our website at https://ir.lexariabioscience.com/sec-filings, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with or otherwise furnish it to the SEC.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have filed with the SEC a registration statement under the Securities Act, relating to the offering of these securities. The registration statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus does not contain all of the information set forth in the registration statement. You can obtain a copy of the registration statement for free at www.sec.gov. The registration statement and the documents referred to below under &#8220;Incorporation of Certain Information By Reference&#8221; are also available on our website, <u>https://ir.lexariabioscience.com/sec-filings</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="ICIBR">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The SEC allows us to &#8220;incorporate by reference&#8221; the information we have filed with it, which means that we can disclose important information to you by referring you to those documents. The information we incorporate by reference is an important part of this prospectus, and later information that we file with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below and any future documents (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) we file with the SEC pursuant to Sections l3(a), l3(c), 14 or l5(d) of the Exchange Act subsequent to the date of this prospectus and prior to the termination of the offering:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">our <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1348362/000164033423002227/lxrp_10k.htm">Annual Report on Form 10-K for the year ended August 31, 2023</a>, filed on November 20, 2023;</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">our Current Reports on Form 8-K, filed on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1348362/000164033423001769/lxrp_8k.htm">October 3, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1348362/000164033423001812/lxrp_8k.htm">October 12, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1348362/000164033423001846/lxrp_8k.htm">October 16, 2023</a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1348362/000164033423001869/lxrp_8k.htm">October 18 2023</a> and <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1348362/000164033423002017/lxrp_8k.htm">November 3, 2023</a> (other than any portions thereof deemed furnished and not filed);</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">our <a href="http://www.sec.gov/Archives/edgar/data/1348362/000164033421000051/lxrp_8a12b.htm">Form 8-A12B, filed on January 11, 2021</a>; and</p></td></tr> <tr style="height:15px"> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="font-size:10pt;font-family:times new roman;text-align:justify;margin:0px">our <a href="http://www.sec.gov/Archives/edgar/data/1348362/000113707006000235/f8a.htm">Form 8-A12G, filed on July 14, 2006</a>.</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All filings filed by us pursuant to the Exchange Act after the date of the initial filing of this registration statement and prior to the effectiveness of such registration statement (excluding information furnished pursuant to Items 2.02 and 7.01 of Form 8-K) shall also be deemed to be incorporated by reference into the prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">You should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different information. Any statement contained in a document incorporated by reference into this prospectus will be deemed to be modified or superseded for the purposes of this prospectus to the extent that a later statement contained in this prospectus or in any other document incorporated by reference into this prospectus modifies or supersedes the earlier statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You should not assume that the information in this prospectus is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We will provide without charge to each person to whom a copy of this prospectus is delivered, upon written or oral request, a copy of any or all of the reports or documents that have been incorporated by reference in this prospectus but not delivered with this prospectus (other than an exhibit to these filings, unless we have specifically incorporated that exhibit by reference in this prospectus). Any such request should be addressed to us at:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Lexaria Bioscience Corp.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Attn: Corporate Secretary</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">100-740 McCurdy Road</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Kelowna, British Columbia, Canada, VIX 2P7</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1-250-765-6424&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">You may also access the documents incorporated by reference in this prospectus through our website at <u>https://ir.lexariabioscience.com/sec-filings</u>. Except for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which it forms a part.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>1,618,330 Shares</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><img src="lxrp_s1img2.jpg"></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">COMMON STOCK</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">PROSPECTUS</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"></p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lxrp_s1img1.jpg
<TEXT>
begin 644 lxrp_s1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" #< :$# 2(  A$! Q$!_\0
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M>M:=%#=*]V,8QCRQ*C'E%HHHJRB%F559F^50OS-5+^V](_Z"EG_W_6H/$_\
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MXANK>.XMV62&1=Z.K?*R_P!X5^:_Q2O+K4/BUXHNKQF\YM0F5E;^%59E5?\
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M35]<?L@QQQ^%?$TWEKYC7D:LW\3*L>Y?_0FKY'U7_D,7W_7>3_T)J^OOV/\
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MI-Y)97\-XGRLCJW_ 'S7IDVB>%61EELK2-O]G;'_ .@[:;%X7\+LVZ*U1O\
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M6-/\&^&FN/+C58U\N")?EWM_"M?/M_K5YJVH2:A?3-)-*WS?W5_V5_NK6O\
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M?_$_-N_O?=J9:S]TJ,;1U,*3X+Z7:,TGAWQ-K6BR,?E6*YW1K_P'Y6_\>H\
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M6EW&ES2[MUM<KB2/:S+\WRKUQN_X%71UEJ:KX1U%%%!04444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>lxrp_s1img2.jpg
<TEXT>
begin 644 lxrp_s1img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  4$! 0$ P4$! 0&!04&" T(" <'
M"! +# D-$Q 4$Q(0$A(4%QT9%!8<%A(2&B,:'!X?(2$A%!DD)R0@)AT@(2#_
MVP!# 04&!@@'" \(" \@%1(5(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @("#_P  1" #< :$# 2(  A$! Q$!_\0
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M>M:=%#=*]V,8QCRQ*C'E%HHHJRB%F559F^50OS-5+^V](_Z"EG_W_6H/$_\
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MXANK>.XMV62&1=Z.K?*R_P!X5^:_Q2O+K4/BUXHNKQF\YM0F5E;^%59E5?\
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M35]<?L@QQQ^%?$TWEKYC7D:LW\3*L>Y?_0FKY'U7_D,7W_7>3_T)J^OOV/\
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MI-Y)97\-XGRLCJW_ 'S7IDVB>%61EELK2-O]G;'_ .@[:;%X7\+LVZ*U1O\
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M6-/\&^&FN/+C58U\N")?EWM_"M?/M_K5YJVH2:A?3-)-*WS?W5_V5_NK6O\
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M?_$_-N_O?=J9:S]TJ,;1U,*3X+Z7:,TGAWQ-K6BR,?E6*YW1K_P'Y6_\>H\
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M6EW&ES2[MUM<KB2/:S+\WRKUQN_X%71UEJ:KX1U%%%!04444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
